Skip to main content
SpringerLink
Log in

Clinical Prescribing of Allergic Rhinitis Medication in the Preschool and Young School-Age Child

What are the Options?

  • Review Article
  • Published:
BioDrugs Aims and scope Submit manuscript

Abstract

Allergic rhinitis (AR) is the most common chronic condition in children and is estimated to affect up to 40% of all children. It is usually diagnosed by the age of 6 years. The major impact in children is due to co-morbidity of sinusitis, otitis media with effusion, and bronchial asthma. AR also has profound effects on school absenteeism, performance and quality of life.

Pharmacotherapy for AR should be based on the severity and duration of signs and symptoms. For mild, intermittent symptoms lasting a few hours to a few days, an oral second-generation antihistamine should be used on an as-needed basis. This is preferable to a less expensive first-generation antihistamine because of the effect of the latter on sedation and cognition. Four second-generation antihis-tamines are currently available for children under 12 years of age: cetirizine, loratadine, fexofenadine and azelastine nasal spray; each has been found to be well tolerated and effective. There are no clearcut advantages to distinguish these antihistamines, although for children under 5 years of age, only cetirizine and loratadine are approved. Other agents include pseudoephedrine, an oral vasoconstrictor, for nasal congestion, and the anticholinergic nasal spray ipratropium bromide for rhinorrhoea. Sodium cromoglycate, a mast cell stabiliser nasal spray, may also be useful in this population.

For patients with more persistent, severe symptoms, intranasal corticosteroids are indicated, although one might consider azelastine nasal spray, which has anti-inflammatory activity in addition to its antihistamine effect. With the exception of fluticasone propionate for children aged 4 years and older, and mometasone furoate for those aged 3 years and older, the other intranasal corticosteroids including beclomethasone dipropionate, triamcinolone, flunisolide and budesonide are approved for children aged 6 years and older. All are effective, so a major consideration would be cost and safety. For short term therapy of 1 to 2 months, the first-generation intranasal corticosteroids (beclomethasone dipropionate, triamcinolone, budesonide and flunisolide) could be used, and mometasone furoate and fluticasone propionate could be considered for longer-term treatment. Although somewhat more costly, these second-generation drugs have lower bio-availability and thus would have a better safety profile.

In patients not responding to the above programme or who require continuous medication, identification of specific triggers by an allergist can allow for specific avoidance measures and/or immunotherapy to decrease the allergic component and increase the effectiveness of the pharmacological regimen.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV
Table V
Table VI

Similar content being viewed by others

References

  1. Newacheck PW, Stoddard JJ. Prevalence and impact of multiple childhood chronic illnesses. J Pediatr 1994; 124: 40–8

    Article  CAS  PubMed  Google Scholar 

  2. Wright AC, Holberg CJ, Martinez FD, et al. Epidemiology of physician diagnosed allergic rhinitis in childhood. Pediatrics 1994; 94: 895–901

    CAS  PubMed  Google Scholar 

  3. Stachen DP, Sibbald B, Weiland SK, et al. Worldwide variation in the prevalence of symptoms of allergic rhinoconjunctivitis in children: the international study of asthma and allergy in childhood (ISAAC). Pediatr Allergy Immunol 1997; 8: 161–76

    Article  Google Scholar 

  4. Ray NF, Baranuik JN, Thamer M, et al. Direct expenditure for treatment of allergic rhinitis in 1996, including contributions of related airway illnesses. J Allergy Clin Immunol 1999; 103: 401–7

    Article  CAS  PubMed  Google Scholar 

  5. Dykewicz MS, Fireman S, Skoner DP, et al. Complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 1998; 81: 478–518

    Article  CAS  PubMed  Google Scholar 

  6. Rachelefsky GS. National guidelines needed to manage rhinitis and prevent complications. Ann Allergy Asthma Immunol 1999; 82: 296–305

    Article  CAS  PubMed  Google Scholar 

  7. Vuurman EF, Van Veggel LM, Uiterwijk MM, et al. Season allergic rhinitis and antihistamine effects on children’s learning. Ann Allergy 1993; 71: 121–6

    CAS  PubMed  Google Scholar 

  8. Fireman P. Therapeutic approaches to allergic rhinitis: treating the child. J Allergy Clin Immunol 2000; 105: S616–21

    Article  CAS  PubMed  Google Scholar 

  9. Smith L. Special considerations for the child with airway disease. J Allergy Clin Immunol 1998; 101: S370–2

    Article  CAS  PubMed  Google Scholar 

  10. White M. Mediators of inflammation and the inflammatory process. J Allergy Clin Immunol 1999; 103: S378–81

    Article  CAS  PubMed  Google Scholar 

  11. Galant SP, Wilkinson R. Allergic rhinitis: assessing current therapeutic options. Formulary 1999; 34: 1016–32

    CAS  Google Scholar 

  12. Simons FER, Simons KJ. The pharmacology and use of H1 receptor antagonist drugs. N Engl J Med 1994; 330: 1663–70

    Article  CAS  PubMed  Google Scholar 

  13. Naclerio RM, Proud D, Kagey-Sobotoka A, et al. The effect of cetirizine in the early allergic response. Laryngoscope 1989; 1999: 596–9

    Google Scholar 

  14. Charlesworth EW, Kagey-Sobotoka A, Norman PS, et al. Effect of cetirizine in mast cell mediator release in cellular traffic during the cutaneous late phase reaction. J Allergy Clin Immunol 1989; 83: 905–12

    Article  CAS  PubMed  Google Scholar 

  15. McNeely W, Wiseman LR. Intranasal azelastine. Review of its efficacy and the management of AR. Drugs 1998; 56: 91–114

    Article  CAS  PubMed  Google Scholar 

  16. Lasley MV, Shapiro GG. Rhinitis and sinusitis in children. Pediatr Allergy Immunol 1999; 19: 437–52

    Google Scholar 

  17. Milgrom H, Bender B. Adverse effects of medications for rhinitis. Ann Allergy Asthma Immunol 1997; 78: 439–46

    Article  CAS  PubMed  Google Scholar 

  18. Bergen Jr SS. Appetite stimulating properties of cyproheptadine. Am Dis Child 1964; 108: 270–3

    Google Scholar 

  19. Meltzer EO. Comparative safety of H1 antihistamines. Ann Allergy 1991; 67: 625–33

    CAS  PubMed  Google Scholar 

  20. Simons FER. H1 receptor antagonists in children. In histamine and H1 receptor antagonists and allergic disease. Simons FER, editor. New York: Marcel Dekker, 1996: 329–56

    Google Scholar 

  21. Simons FER. H1 receptor antagonists in children. In: Simons FER, editor. Histamine and H1 receptor antagonists and allergic disease. New York: Marcel Dekker, 1996: 175–213

    Google Scholar 

  22. Salmun LM, Herron JM, Banfield C, et al. The pharmacokinetics, electrocardiographic effects, and tolerability of loratadine syrup in children aged 2 to 5 years. Clin Ther 2000; 22: 613–21

    Article  CAS  PubMed  Google Scholar 

  23. Simons FER, Bergman JN, Watson WTA. The clinical pharmacology of fexofenadine in children. J Allergy Clin Immunol 1996; 98: 1062–4

    Article  CAS  PubMed  Google Scholar 

  24. 2000 Drug Topics Red Book. Medical Economics Company Inc., Mount Vail, NJ

  25. Tinkelman DJ, Kemp J, Mitchell DQ, et al. Treatment of season allergic rhinitis in children with cetirizine and chlorphenira-mine. A multi-center study. Pediatr Asthma Allergy Immunol 1996; 10: 9–17

    Article  Google Scholar 

  26. Baelde Y, Dupont P. Cetirizine in children with chronic allergic rhinitis. Drug Invest 1992; 4: 466–72

    Article  Google Scholar 

  27. Lutsky BN, Klose P, Melon M, et al. A comparative study of the efficacy and safety of loratadine and terfenadine suspension in the treatment of 3 to 6 year old children with SAR. Clin Ther 1993; 15: 855–65

    CAS  PubMed  Google Scholar 

  28. Fexofenadine package insert. Feb 2000; Aventis, Kansas City, MO

  29. Long J, Meltzer EO, ScottDawdy K, et al. Safety of fexofenadine HCL in children treated for seasonal allergic rhinitis.J Allergy Clin Immunol 1999; 103: S254

    Google Scholar 

  30. Herman D, Garay R, LeGal M. A randomized double-blind placebo controlled study of azelastine nasal spray in children with perennial rhinitis. Int J Pediatr Otorhinolaryngol 1997; 39: 1–8

    Article  CAS  PubMed  Google Scholar 

  31. Astelins RNasal Spray package insert. Cranbury, NJ: Wallace Laboratories, 2000

  32. Storms WW, Bodeman SF, Nathan RA, et al. SCH 434: A new antihistamine-decongestant for season allergic rhinitis. J Allergy Clin Immunol 1989; 83: 1083–90

    Article  CAS  PubMed  Google Scholar 

  33. Laforce C. Use of nasal steroids in managing allergic rhinitis. J Allergy Clin Immunol 1999; 103: S388–94

    Article  CAS  PubMed  Google Scholar 

  34. Meltzer EO. Treatment options for the child with allergic rhinitis. Clin Pediatr 1998; 37: 1–10

    Article  CAS  Google Scholar 

  35. Allen DB. Systemic effect of intranasal steroids: an endocrinologist’s perspective. J Allergy Clin Immunol 2000; 106: S179–90

    Article  CAS  PubMed  Google Scholar 

  36. Thorsson L, Borga O, Edsbacker S. Systemic availability of budesonide after nasal administration of three different formulations: pressurized aerosol, aqueous spray pump, and powder. Br J Pharmacol 1999; 47: 619–24

    CAS  Google Scholar 

  37. Darrendorf H, Hochhaus G, Meibohm B, et al. Pharmacokinetics and phamacodynamics of inhaled corticosteroids. J Allergy Clin Immunol 1998; 101: S440–6

    Article  Google Scholar 

  38. Kaliner M, Eagleston PA, Matthews KP. Rhinitis and bronchial asthma. JAMA 1987; 258: 2851–73

    Article  CAS  PubMed  Google Scholar 

  39. Bernstein IL. Is the use of benzalkonium chloride as a preservative for nasal formulation a safety concern? A cautioning note based on compromised mucociliary transport. J Allergy Clin Immunol 2000; 105: 39–46

    Article  CAS  PubMed  Google Scholar 

  40. Pedersen S, Steffensen G, Ekman S, et al. Pharmacokinetics of budesonide in children with asthma. Eur J Clin Pharmacol 1987; 31: 579–82

    Article  CAS  PubMed  Google Scholar 

  41. Wolthers OD. Systemic activity vs. systemic adverse effects of nasal glucocorticoids in treatment of allergic rhinitis. Acta Paediatr 2000; 89: 1158–66

    Article  CAS  PubMed  Google Scholar 

  42. Skoner DP, Rachelefsky GS, Meltzer EO, et al. Detection of growth suppression in children during treatment with intranasal beclomethasone dipropionate. Pediatrics 2000; 105(2): E23

    Article  CAS  PubMed  Google Scholar 

  43. Wolthers OD, Pedersen S. Short term growth in children with allergic rhinitis treated with oral antihistamines, depot and intranasal glucocorticoids. Acta Paediatr 1993; 82: 635–40

    CAS  PubMed  Google Scholar 

  44. Wolthers OD, Pedersen S. Knemometric assessment of systemic activity of once daily intranasal dry powder of budesonide in children. Allergy 1994; 49: 96–9

    Article  CAS  PubMed  Google Scholar 

  45. Agertoft L, Pedersen S. Short term lower leg growth rate in children with rhinitis treated with intranasal mometasone furoate and budesonide. J Allergy Clin Immunol 1999; 104: 948–52

    Article  CAS  PubMed  Google Scholar 

  46. Hermanussen M, Burmeister J. Standards for the predictive accuracy of short term body height and lower leg length measures in half annual growth rates. Arch Dis Child 1989; 64: 259–63

    Article  CAS  PubMed  Google Scholar 

  47. Schenkel EJ, Skoner DP, Bronsky EA, et al. Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray. Pediatrics 2000; 105(2): E22

    Article  CAS  PubMed  Google Scholar 

  48. Allen DB, Bronsky EA, La Force CF, et al. Growth in asthmatic children treated with fluticasone propionate. J Pediatrics 1998; 132: 472–7

    Article  CAS  Google Scholar 

  49. The Childhood Asthma Management Program Research Group. Long term effects of budesonide or nedocromil in children with bronchial asthma. N Engl J Med 2000; 343: 1054–63

    Article  Google Scholar 

  50. Agertoft L, Pedersen S. Effects of long term treatment with inhaled budesonide on adult height in children with bronchial asthma. N Engl J Med 2000; 343: 1064–9

    Article  CAS  PubMed  Google Scholar 

  51. Nasalcrom package insert. Rochester, NY: Fisons Corp., 1994

  52. Welsh PW, Yuninger JW, Kern AB, et al. Pre-school IgE ragweed antibody levels as a predictor of response to therapy of ragweed hay fever with intranasal cromolyn sodium. J Allergy Clin Immunol 1977; 60: 104–9

    Article  CAS  PubMed  Google Scholar 

  53. Meltzer EO, Orgel HA, Biondi R, et al.Ipratropium nasal spray in children with perennial rhinitis. Ann Allergy Asthma Immunol 1997; 78: 485–91

    Article  CAS  PubMed  Google Scholar 

  54. Druce HM, Bonner RF, Patow C, et al. Responsive nasal blood flow to neuro hormones as mentioned by laser doppler velocimetry. J Appl Physiol 1983; 57: 1276–80

    Google Scholar 

Download references

Acknowledgements

The authors would like to thank Marla Nathan and Rhonda Robles for preparation of the manuscript.

Author information

Authors and Affiliations

  1. University of California, Department of Paediatric Allergy/Immunology, Irvine, California, USA

    Stanley P. Galant

  2. St Joseph Hospital, Department of Pharmacy, Orange, California, USA

    Robert Wilkinson

Authors
  1. Stanley P. Galant
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert Wilkinson
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Galant, S.P., Wilkinson, R. Clinical Prescribing of Allergic Rhinitis Medication in the Preschool and Young School-Age Child. BioDrugs 15, 453–463 (2001). https://doi.org/10.2165/00063030-200115070-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00063030-200115070-00004

Keywords

Search

Navigation